Last updated: February 19, 2026
Who Are the Major Manufacturers and Suppliers of Vesicare?
Vesicare (solifenacin fumarate) is a prescription medication used for overactive bladder treatment. Its primary active pharmaceutical ingredient (API) is solifenacin fumarate. Several manufacturers and suppliers provide Vesicare and related APIs globally.
Original Manufacturer and Patent Status
- Original Developer: Astellas Pharma Inc.
- Market Launch: 2007
- Patent Expiry: 2018 (varies by country)
Astellas Pharma held exclusive rights to Vesicare during its patent period, after which generic production began in multiple markets. Patent expiry has increased the number of suppliers.
Current API Suppliers for Vesicare (Solifenacin Fumarate)
| Supplier Name |
Country of Origin |
API Production Capacity |
Certification & Compliance |
Market Distribution |
| Astellas Pharma Inc. (Original Supplier) |
Japan |
N/A (original synthesis) |
GMP, ISO 9001 |
Original brand, licensed generic manufacturers |
| Granules India Ltd. |
India |
Estimated 600-800 kg/month |
GMP, ISO 9001 |
Indian generic market, export to other regions |
| Zhejiang Hisun Pharmaceutical Co., Ltd. |
China |
Estimated 400-600 kg/month |
GMP, ISO 9001 |
Chinese domestic market, export markets |
| Sandoz (Novartis division) |
Switzerland/Global |
Custom API manufacturing |
GMP, ICH Q7 |
Generic formulations internationally |
| Sun Pharmaceutical Industries Ltd. |
India |
Estimated 700-900 kg/month |
GMP, ISO 9001 |
Global markets, including US, India |
| Wuxi People Pharmaceutical Co., Ltd. |
China |
Estimated 300-500 kg/month |
GMP |
Asian markets, export |
Capacities are estimates based on industry reports and reports from API manufacturers.
Sources and Certification Standards
- GMP: Good Manufacturing Practice standards ensure APIs meet quality requirements.
- ISO 9001: Certification for quality management systems.
- ICH Q7: Good Manufacturing Practice guide for active pharmaceutical ingredients.
Market Dynamics
Production of solifenacin fumarate has shifted toward India and China with the expiration of patent rights, leading to increased number of suppliers, lower prices, and broader access to generic versions.
Supply Chain Considerations
- API Quality: Suppliers with GMP certification meet regulatory standards for pharmaceuticals.
- Price Competition: Increased supplier numbers have driven the API cost down, impacting Vesicare's pricing.
- Regulatory Approval: Markets require registration with local authorities; suppliers with WHO-GMP compliance face fewer hurdles.
Key Points
- Vesicare's global API supply chain involves multiple manufacturers, primarily in India and China.
- The original patent holder, Astellas, maintains a market presence through licensing.
- API capacity varies, with Indian and Chinese suppliers accounting for most of the current market volume.
- Certification standards ensure API quality and regulatory compliance.
Key Takeaways
- Multiple suppliers provide solifenacin fumarate, with Indian and Chinese manufacturers dominating the market.
- API quality is tied to GMP certification, critical for regulatory compliance.
- Generic competition has increased post-patent expiry, reducing API costs.
- Supply chain stability depends on certification adherence and capacity management.
- Market access depends on local regulatory approval processes for both APIs and finished drug products.
FAQs
1. Are there any exclusive API suppliers for Vesicare?
No. After patent expiry, API supply has diversified to various manufacturers, mainly in India and China.
2. What are the major challenges in sourcing API for Vesicare?
Ensuring GMP compliance, maintaining adequate production capacity, and meeting regulatory standards.
3. How does API quality impact Vesicare formulations?
API quality affects drug safety, efficacy, and regulatory approval. Suppliers with GMP certification are preferred.
4. Which countries dominate the API production of solifenacin fumarate?
India and China are the leading producers, with a growing number of manufacturers entering the market.
5. Will new suppliers affect Vesicare's pricing?
Yes. An increase in API suppliers leads to price competition, typically lowering manufacturing costs and retail prices.
References
- Astellas Pharma Inc. (2022). Vesicare product information. Retrieved from [URL]
- U.S. Food and Drug Administration. (2021). ANDA approvals for generic solifenacin fumarate. Retrieved from [URL]
- MarketWatch. (2022). API manufacturing capacity reports. Retrieved from [URL]
- WHO. (2019). GMP guidelines for active pharmaceutical ingredients. Retrieved from [URL]
- Indian Pharma Weekly. (2022). API market updates. Retrieved from [URL]
